Medicines & Healthcare products Regulatory Agency

MHRA

Public Assessment Report

National Procedure

SILDENAFIL 50 MG FILM-COATED TABLETS
SILDENAFIL 100 MG FILM-COATED TABLETS
(sildenafil citrate)

PLGB 39305/0015-0016

Umedica Limited

LAY SUMMARY

Sildenafil 50 mg film-coated tablets
Sildenafil 100 mg film-coated tablets
(sildenafil citrate)

This is a summary of the Public Assessment Report (PAR) for Sildenafil 50 mg and 100 mg film-coated tablets. It explains how these products were assessed and their authorisation recommended, as well as their conditions of use. It is not intended to provide practical advice on how to use these products.

These products will be referred to as Sildenafil tablets in this lay summary for ease of reading.

For practical information about using Sildenafil tablets, patients should read the Patient Information Leaflet (PIL) or contact their doctor or pharmacist.

What are Sildenafil tablets and what are they used for?
These products have been authorised by MHRA for Great Britain (consisting of England, Scotland and Wales). These procedures take into account the outcome of mutual recognition (MR) procedures in European Union Member States (and/or Iceland, Liechtenstein, Norway) on 24 May 2019 (NL/H/4791/001-002/MR). This is known as the MR/DC Decision Reliance Procedure.

These applications are for generic medicines. This means that these medicines are the same as, and considered interchangeable with, reference medicines already authorised in the United Kingdom (UK) and European Union (EU) called Viagra 50 mg and 100 mg film-coated tablets.

Sildenafil tablets are a treatment for adult men with erectile dysfunction, sometimes known as impotence. This is when a man cannot get, or keep a hard, erect penis suitable for sexual activity.

How do Sildenafil tablets work?
Sildenafil tablets contains the active substance sildenafil which belongs to a group of medicines called phosphodiesterase type 5 (PDE5) inhibitors. It works by helping to relax the blood vessels in the penis, allowing blood to flow into the penis. These medicines will only help the patient to get an erection if they are sexually stimulated.

How are Sildenafil tablets used?
The pharmaceutical form of these medicines is a film-coated tablet and the route of administration is oral.

The recommended starting dose is 50 mg.
Patients should not take this medicine more than once a day.
This medicine should be taken about one hour before the patient plans to have sex. The tablet should be swallowed whole with a glass of water.

If the patient feels that the effect of these products is too strong or too weak, they should talk to their doctor or pharmacist.

Sildenafil tablets will only help the patient to get an erection if they are sexually stimulated. The amount of time this medicine takes to work varies from person to person, but it normally takes between half an hour and one hour. Patients may find that this medicine takes longer to work if they take it with a heavy meal.

If this medicine does not help the patient to get an erection or if the erection does not last long enough for the patient to complete sexual intercourse, they should tell their doctor.

For further information on how Sildenafil tablets are used, refer to the PIL and Summaries of Product Characteristics (SmPCs) available on the Medicines and Healthcare products Regulatory Agency (MHRA) website.

These medicines can only be obtained with a prescription.

The patient should always take the medicine exactly as their doctor/pharmacist has told them. The patient should check with their doctor or pharmacist if they are not sure.

What benefits of Sildenafil tablets have been shown in studies?
Because Sildenafil tablets are generic medicines, studies in healthy volunteers have been limited to tests to determine that they are bioequivalent to the reference medicines. Two medicines are bioequivalent when they produce the same levels of the active substance in the body.

What are the possible side effects of Sildenafil tablets?
For the full list of all side effects reported with these medicines, see Section 4 of the PIL or the SmPCs available on the MHRA website.

If a patient gets any side effects, they should talk to their doctor, pharmacist or nurse. This includes any possible side effects not listed in the product information or the PIL that comes with the medicine. Patients can also report suspected side effects themselves, or a report can be made on their behalf by someone else who cares for them, directly via the Yellow Card scheme at www.yellowcard.mhra.gov.uk or search for 'MHRA Yellow Card' online. By reporting side effects, patients can help provide more information on the safety of these medicines.

Because Sildenafil tablets are generic medicines and are bioequivalent to the reference medicines, their benefits and possible side effects are considered to be the same as the reference medicines.

Why were Sildenafil tablets approved?
MHRA decided that the benefits are greater than the risks and recommended that these medicines can be approved for use.

What measures are being taken to ensure the safe and effective use of Sildenafil tablets?
As for all newly authorised medicines, a Risk Management Plan (RMP) has been developed for Sildenafil tablets. The RMP details the important risks of Sildenafil tablets, how these risks can be minimised, any uncertainties about Sildenafil tablets (missing information), and how more information will be obtained about the important risks and uncertainties.

The following safety concerns have been recognised for Sildenafil tablets:
Important identified risks:

- Nitrate Interaction

Important potential risks:

- Non-arteritic anterior ischaemic optic neuropathy (NAION)
- Sudden hearing loss
- Eye haemorrhage

Missing information:

- Severe hepatic impairment

The information included in the SmPCs and the PIL is compiled based on the available quality, non-clinical and clinical data, and includes appropriate precautions to be followed by healthcare professionals and patients. Side effects of Sildenafil tablets are continuously monitored and reviewed including all reports of suspected side-effects from patients, their carers, and healthcare professionals.

An RMP and a summary of the pharmacovigilance system have been provided with these applications and are satisfactory.

Other information about Sildenafil tablets
Marketing authorisations were granted in Great Britain on 16 May 2022.

The full PAR for Sildenafil tablets follows this summary.

This summary was last updated in June 2022.

TABLE OF CONTENTS

I. INTRODUCTION

Based on the review of the data on quality, safety and efficacy, the Medicines and Healthcare products Regulatory Agency (MHRA) considered that the applications for Sildenafil 50 mg and 100 mg film-coated tablets (PLGB 39305/0015-0016) could be approved.

The products are approved for the following indications:
In adult men with erectile dysfunction, which is the inability to achieve or maintain a penile erection sufficient for satisfactory sexual performance. In order for sildenafil to be effective, sexual stimulation is required.

These medicines contain the active substance, sildenafil.

The physiological mechanism responsible for erection of the penis involves the release of nitric oxide (NO) in the corpus cavernosum during sexual stimulation. Nitric oxide then activates the enzyme guanylate cyclase, which results in increased levels of cyclic guanosine monophosphate (cGMP), producing smooth muscle relaxation in the corpus cavernosum and allowing inflow of blood.

Sildenafil is a potent and selective inhibitor of cGMP specific phosphodiesterase type 5 (PDE5) in the corpus cavernosum, where PDE5 is responsible for degradation of cGMP. Sildenafil has a peripheral site of action on erections. Sildenafil has no direct relaxant effect on isolated human corpus cavernosum but potently enhances the relaxant effect of nitric oxide (NO) on this tissue. When the NO/cGMP pathway is activated, as occurs with sexual stimulation, inhibition of PDE5 by sildenafil results in increased corpus cavernosum levels of cGMP. Therefore, sexual stimulation is required in order for sildenafil to produce its intended beneficial pharmacological effects.

These products have been authorised by MHRA for Great Britain (consisting of England, Scotland and Wales). These procedures take into account the outcome of mutual recognition (MR) procedures in European Union Member States (and/or Iceland, Liechtenstein, Norway) on 24 May 2019 (NL/H/4791/001-002/MR). For the scientific discussion of the quality, non-clinical and clinical assessment conducted during the MR procedures, please refer to the Reference Member State (RMS) Public Assessment Report, available on the RMS regulatory agency website or on the Heads of Medicines Agencies website.

These applications were approved under Regulation 51A of the Human Medicines Regulation 2012, as amended (previously Article 10.1 of Directive 2001/83/EC, as amended).

The MHRA has been assured that acceptable standards of Good Manufacturing Practice (GMP) are in place for these products at all sites responsible for the manufacture, assembly and batch release of these products.

A Risk Management Plan (RMP) and a summary of the pharmacovigilance system have been provided with these applications and are satisfactory.

Marketing Authorisations were granted on 16 May 2022.

II. ASSESSOR'S COMMENTS ON THE PRODUCT INFORMATION

SUMMARY OF PRODUCT CHARACTERITICS (SmPC)

The SmPCs are in line with current guidelines and are satisfactory.

PATIENT INFORMATION LEAFLET

The PIL is in line with current guidelines and is satisfactory.

LABEL

The labelling is in line with current guidelines and is satisfactory.

III. QUALITY ASPECTS

MHRA considered that the quality data submitted for these applications is satisfactory.

The grant of marketing authorisations is recommended.

IV. NON-CLINICAL ASPECTS

MHRA considered that the non-clinical data submitted for these applications is satisfactory.

The grant of marketing authorisations is recommended.

V. CLINICAL ASPECTS

MHRA considered that the non-clinical data submitted for these applications is satisfactory.

The grant of marketing authorisations is recommended.

VI. RISK MANAGEMENT PLAN (RMP)

The applicant has submitted an RMP, in accordance with the requirements of Regulation 182 of The Human Medicines Regulation 2012, as amended. The applicant proposes only routine pharmacovigilance and routine risk minimisation measures for all safety concerns. This is acceptable.

VII. USER CONSULTATION

A suitable patient Information Leaflet (PIL) text has been evaluated. The applicant has committed to submitting a PIL mock-up and user consultation study prior to placing the product on the market.

The PIL approved during the MR procedure has been evaluated via a user consultation study in accordance with legal requirements. The results show that the PIL meets the criteria for readability as set out in the Guideline on the readability of the label and package leaflet of medicinal products for human use.

VIII. OVERALL CONCLUSION, BENEFIT/RISK AND RECOMMENDATION

The quality of the products is acceptable, and no new non-clinical or clinical safety concerns have been identified. The benefit/risk balance is, therefore, considered to be positive.

The Summaries of Product Characteristics (SmPCs), Patient Information Leaflet (PIL) and labelling are satisfactory.

In accordance with legal requirements, the current approved UK versions of the SmPCs and PIL for these products are available on the MHRA website.

The following text is the currently approved label text. No label mock-ups have been

provided for these products. In accordance with legal requirements, these products shall not be marketed until approval of the full-colour label mock-ups has been obtained.

LABELLING

PARTICULARS TO APPEAR ON BLISTERS OR STRIPS:

Blister [PVC/ALU]

1. NAME OF THE MEDICINAL PRODUCT

Sildenafil 50 mg film-coated tablets

2. NAME OF THE MARKETING AUTHORISATION HOLDER

Umedica Limited

3. EXPIRY DATE

Exp

4. BATCH NUMBER

Batch

5. OTHERS

PARTICULARS TO APPEAR ON THE OUTER PACKAGING:
CARTON

1. NAME OF THE MEDICINAL PRODUCT

Sildenafil 50 mg film-coated tablets

2. STATEMENT OF ACTIVE SUBSTANCE(S)

Each tablet contains sildenafil citrate equivalent to 50 mg sildenafil.

3. LIST OF EXCIPIENTS

Lactose
See package leaflet for further information.

4. PHARMACEUTICAL FORM AND CONTENTS

2 film-coated tablets
4 film-coated tablets
8 film-coated tablets
12 film-coated tablets
24 film-coated tablets

5. METHOD AND ROUTE (S) OF ADMINISTRATION

Read the package leaflet before use.
For oral use.

6. SPECIAL WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE SIGHT AND REACH OF CHILDREN

Keep out of the sight and reach of children.

7. OTHER SPECIAL WARNING(S), IF NECESSARY

8. EXPIRY DATE

Exp

9. SPECIAL STORAGE CONDITIONS

Store in the original package in order to protect from moisture.
This medicinal product does not require any special temperature storage conditions.

10. SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS, IF APPROPRIATE

11. NAME AND ADDRESS OF THE MARKETING AUTHORIZATION HOLDER

Umedica Limited
Palladium House,
1/4 Argyll Street,
London, W1F 7LD,
United Kingdom

12. MARKETING AUTHORISATION NUMBER(S)

PL GB 39305/0015

13. BATCH NUMBER

Batch

14. GENERAL CLASSIFICATION FOR SUPPLY

Medicinal product subject to medical prescription

15. INSTRUCTIONS FOR USE

16. INFORMATION IN BRAILLE

Sildenafil 50 mg film-coated tablets

17. UNIQUE IDENTIFIER – 2D BARCODE

2D barcode carrying the unique identifier included

18. UNIQUE IDENTIFIER - HUMAN READABLE DATA

PC:
SN:
NN:

LABELLING

PARTICULARS TO APPEAR ON BLISTERS OR STRIPS:

Blister [PVC/ALU]

1. NAME OF THE MEDICINAL PRODUCT

Sildenafil 100 mg film-coated tablets

2. NAME OF THE MARKETING AUTHORISATION HOLDER

Umedica Limited

3. EXPIRY DATE

Exp

4. BATCH NUMBER

Batch

5. OTHERS

PARTICULARS TO APPEAR ON THE OUTER PACKAGING:
CARTON

1. NAME OF THE MEDICINAL PRODUCT

Sildenafil 100 mg film-coated tablets

2. STATEMENT OF ACTIVE SUBSTANCE(S)

Each tablet contains sildenafil citrate equivalent to 100 mg sildenafil.

3. LIST OF EXCIPIENTS

Lactose
See package leaflet for further information.

4. PHARMACEUTICAL FORM AND CONTENTS

2 film-coated tablets
4 film-coated tablets
8 film-coated tablets
12 film-coated tablets
24 film-coated tablets

5. METHOD AND ROUTE (S) OF ADMINISTRATION

Read the package leaflet before use.
For oral use.

6. SPECIAL WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE SIGHT AND REACH OF CHILDREN

Keep out of the sight and reach of children.

7. OTHER SPECIAL WARNING(S), IF NECESSARY

8. EXPIRY DATE

Exp

9. SPECIAL STORAGE CONDITIONS

Store in the original package in order to protect from moisture.
This medicinal product does not require any special temperature storage conditions.

10. SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS, IF APPROPRIATE

11. NAME AND ADDRESS OF THE MARKETING AUTHORIZATION HOLDER

Umedica Limited
Palladium House,
1/4 Argyll Street,

London, W1F 7LD,
United Kingdom

12. MARKETING AUTHORISATION NUMBER(S)

PL GB 39305/0016

13. BATCH NUMBER

Batch

14. GENERAL CLASSIFICATION FOR SUPPLY

Medicinal product subject to medical prescription

15. INSTRUCTIONS FOR USE

16. INFORMATION IN BRAILLE

Sildenafil 100 mg film-coated tablets

17. UNIQUE IDENTIFIER – 2D BARCODE

2D barcode carrying the unique identifier included

18. UNIQUE IDENTIFIER - HUMAN READABLE DATA

PC:
SN:
NN:

TABLE OF CONTENTS OF THE PAR UPDATE

Steps taken after the initial procedure with an influence on the Public Assessment Report (non-safety variations of clinical significance).

Please note that only non-safety variations of clinical significance are recorded below and in the annexes to this PAR. The assessment of safety variations, where significant changes are made, are recorded on the MHRA website or European Medicines Agency (EMA) website. Minor changes to the marketing authorisation are recorded in the current SmPCs and/or PIL available on the MHRA website.

Application type	**Scope**	**Product information affected**	**Date of grant**	**Outcome**	**Assessment report attached Y/N**